Program Type: Midwest CEPAC

Interventions of Interest For questions please contact Temiwunmi Shobanke, Program Manager, tshobanke@icer.org. View the Key Stakeholder List.

Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy. Tafamidis and acoramidis would achieve common thresholds for cost-effectiveness if priced between $13,600 to $39,000 per year. Final Documents For questions please contact info@icer.org. View […]

Interventions of Interest An independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ensifentrine added to maintenance therapy compared to maintenance therapy alone. ICER calculated a health-benefit price benchmark (HBPB) for ensifentrine between $7,500 to $12,700 per year, and the therapy is priced at $35,400 per year  Final […]

Interventions of Interest: Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; sotatercept would achieve common thresholds for cost-effectiveness if priced between $17,900 to $35,400 per year. Final Documents ICER’s Chief Medical Officer, David Rind, MD: “Pulmonary arterial hypertension is a progressive disease that can lead to debilitating […]

Interventions of Interest: An independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net health benefit over lifestyle management, whereas current evidence for obeticholic acid was deemed inadequate to demonstrate a net health benefit. ICER analyses suggest resmetirom would achieve common thresholds for cost-effectiveness if priced between $39,600 – $50,100 […]

Interventions of Interest: The independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit for fezolinetant when compared to no pharmacological treatment. Using point estimates from short-term clinical trials, analyses suggest this drug would achieve common thresholds for cost-effectiveness if priced between $2,000 – $2,600 per year for women […]

Interventions of Interest: Relyvrio was removed from the market on April 4, 2024. Read ICER’s commentary on Amylyx’s decision to discontinue the drug here. Final Documents ICER’s Chief Medical Officer, David Rind, MD stated: “The votes of the Midwest CEPAC reflected the remaining uncertainties around the benefits of these therapies and the overwhelming certainty that […]